Abstract
The Global Partnership for Effective Diabetes Management was established in 2004 to provide practical guidance to improving glycaemic control for people with type 2 diabetes. Those recommendations have been updated to take account of recent trials assessing the effects of intensive glucose control. We continue to emphasis the importance of early and sustained glycaemic control, aiming for HbA( 1c) 6.5-7% wherever safe and appropriate. Individualisation of targets and the management process is strongly encouraged to accommodate patient circumstances and to avoid hypoglycaemia. Prompt introduction of combinations of agents is suggested when monotherapy is inadequate.Treatments will preferably address the underlying pathophysiology of type 2 diabetes and integrate within a wider programme of care which also aims to reduce modifiable cardiovascular risk factors and better equip patients in the self-management of their condition.
| Original language | English |
|---|---|
| Pages (from-to) | 283-287 |
| Number of pages | 5 |
| Journal | Diabetes and Vascular Disease Research |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 2009 |
Keywords
- biological markers
- blood glucose
- cooperative behavior
- type 2 diabetes mellitus
- combination drug therapy
- evidence-based medicine
- glycosylated hemoglobin A
- humans
- hypoglycemia
- hypoglycemic agents
- individualized medicine
- international cooperation
- practice guidelines as topic
- treatment outcome
Fingerprint
Dive into the research topics of 'What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver